Table 1 Patient demographics and baseline clinical characteristics
|  | ≤1000 mg (N = 198) | > 1000 mg (N = 58) | p-value |
|---|---|---|---|
Demographics | |||
Male, n (%) | 96 (48.5) | 38 (65.5) | 0.025 |
Weight, kg | |||
 Mean (SD) | 77.1 (20.07) | 89.7 (19.40) | < 0.001 |
 ≥ 50 kg, n (%) | 179 (90.4) | 58 (100.0) |  |
 ≥ 75 kg, n (%) | 94 (47.5) | 47 (81.0) |  |
Clinical characteristics | Â | ||
eGFR, mL/min/1.73 m2 | |||
 Mean (SD) | 25.4 (32.37) | 25.7 (11.93) | 0.910 |
 > 30, n (%) | 39 (19.7) | 13 (22.4) |  |
 ≥ 15 to ≤30, n (%) | 122 (61.6) | 38 (65.5) |  |
 < 15, n (%) | 37 (18.7) | 7 (12.1) |  |
Hb, g/L (n) | (198) | (57) | Â |
 Mean (SD) | 100.6 (11.65) | 102.5 (10.92) | 0.263 |
Ferritin, μg/L (n) | (157) | (45) |  |
 Mean (SD) | 161.9 (188.74) | 111.9 (103.19) | 0.022 |
 Median (Q1, Q3) | 106.0 (52.0, 170.0) | 68.0 (39.0, 137.0) |  |
TSAT, % (n) | (97) | (31) | Â |
 Mean (SD) | 15.8 (6.58) | 13.7 (6.03) | 0.108 |
Platelets, × 109/L (n) | (143) | (45) |  |
 Mean (SD) | 249.9 (88.12) | 222.1 (96.99) | 0.091 |
Concomitant ESA, IUa | |||
 Receiving ESA, n (%) | 43 (21.7) | 15 (25.9) |  |
Cumulative monthly ESA doseb | |||
 Mean (SD) | 9505 (12907) | 7570 (4963) | 0.419 |
 Median | 6000 | 7000 |  |
FACIT-Fatigue Total score (n) | (196) | (58) | Â |
 Mean (SD) | 25.5 (13.71) | 24.1 (13.06) | 0.491 |